Market Overview

UPDATE: Morgan Stanley Upgrades Align Technology to Equal-Weight on Trends, Limited Competition

Share:
Related ALGN
Morgan Stanley Lists Top SMID Stocks To Buy And Sell Headed Into 2017
Align's New Direct-To-Consumer Focus Earns It A Higher Price Target From Stifel

Morgan Stanley raised its rating on Align Technology (NASDAQ: ALGN) from Underweight to Equal-weight and suspended its previous $25 price target.

Morgan Stanley said, "Our Underweight thesis anticipated pressure from consumer spending and competition. Consumer pressure has emerged and pressured growth and valuation, but FDA barriers continue to restrain potential competitors while buying time for Align to expand its low end product line and reduce price to limit potential discounts from new entrants. Our base case forecast for ~8-10% organic growth in 2013 (1% < consensus) reflects (i) stable 10% new customer adds per year; (ii) price decline moderation to -3%; and (iii) utilization growth, particularly in the orthodontist channel. We assume US discretionary spend recovers, competitors are slow to capture share if approved, and Align wins in litigation vs. ClearCorrect; visibility on each is limited."

Align Technology closed at $28.40 on Wednesday.

Latest Ratings for ALGN

DateFirmActionFromTo
Nov 2016Stifel NicolausMaintainsBuy
Oct 2016BairdDowngradesOverweightNeutral
Jul 2016Stifel NicolausMaintainsBuy

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALGN)

View Comments and Join the Discussion!